Heartflow Inc. Common Stock vs IQVIA Holdings Inc. Common Stock — how do they compare? Heartflow Inc. Common Stock trades at $49.44 (market cap $4.38B), while IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 9.8× Heartflow Inc. Common Stock's market cap, and Heartflow Inc. Common Stock is more actively traded (1,454,420 versus 1,333,456). Which is the better fit depends on your goals — on Pluang, investors hold Heartflow Inc. Common Stock for 0 Days and IQVIA Holdings Inc. Common Stock for 6 Days on average.
| HTFL | IQV | |
|---|---|---|
Market Cap | $4.38B | $42.91B |
Volume | 1,454,420 | 1,333,456 |
Sector | Health | Health |
52-Week High | $52.21 | $275.02 |
52-Week Low | $20.49 | $156.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $4.24B | $57.07B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HeartFlow, Inc. develops AI-powered software that analyzes coronary CT angiography scans to build personalized 3D heart models for coronary artery disease diagnosis, including its FFRct Analysis, Plaque Analysis, and Roadmap Analysis tools.
Read more on HTFL →IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →